Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B

• المؤلفون الرئيسيون: Gane E., Wang Y., Liaw Y., Hou J., Thongsawat S., Wan M., Moon Y., Jia J., Chao Y., Niu J., Leung N., Samuel D., Hsu C., Bao W., Lopez P., Avila C.
• التنسيق: دورية
• منشور في: 2017
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953315167&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/43070

Background: In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB). Aims: To investigate the long-term efficacy and safety of telbivudine in the telbivudine-treated cohort from the GLOBE trial. Methods: Virological and bioch...